BioAge Labs is an interesting anti-aging research company, as they are looking to identify the mechanisms of healthy human longevity and thereby reveal potential drug targets for diseases associated with aging. They have a well established pipeline and funding to enable their pursuit of bringing these solutions to market.
BioAge Labs has the following mission statement:
We are harnessing the biology of human aging to develop new therapies for metabolic diseases
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The solution
BioAge Labs are investigating several different avenues to establish their business. The most interesting one from the perspective of anti-aging research is the so-called Discovery program. Outside of this they are also looking into an oral weight loss solution named Azelaprag, as well as another oral drug to be indicated for neuroinflammation.
Pipeline
You can view their official pipeline in the below image from their website:
As it appears from their pipeline they are well ahead with their Azelaprag solution, however, in recent news BioAge Labs announces the discontinuation of their Phase 2 trial named STRIDES, which was meant to evaluate Azelaprag in combination with Tirzepatide for the treatment of obesity.
Aside from this they are planning a pilot study for Azeleprag in acute muscle atrophy (also known as sarcopenia).
Although these conditions are not directly related to anti-aging, they are very much important since a of lot people die from the conditions associated with obesity, and muscle atrophy can significantly lower your chances of survival in a hospital setting later in life as well.
BGE-100 is developed to inhibit the inflammasome on the basis that chronic inflammasome activation leads to pathologic inflammation that drives a vast number of immunologic and fibrotic disorders. As such the aim is to correct chronic activation of the inflammasome, which is associated with aging. BGE-100 has not yet reached clinical trials, but it should be interesting to follow the developments for this solution.
Following the unfortunate discontinuation of Azelaprag combined with Tirzepatide BioAge Labs also announced that they will continue to advance the BGE-100 program. Here they highlighted the IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025.
The most interesting solution here is unfortunately also the least progressed according to BioAge Labs’ pipeline.
Platform
The Discovery platform is unfortunately undisclosed, but there is some information related to the platform on how it can facilitate the identification of key molecular mechanisms of healthy human longevity and reveal new drug targets for diseases associated with aging. The key driver for the platform to facilitate all of this being the use of cutting edge multi-omics to analyze their proprietary data.
The following image from their official website is the extend of public information on the platform illustrated as an infographic to provide a better overview:
The company
BioAge Labs was established in 2015, and has its headquarters in Richmond, CA, USA. The company was founded by Kristen Fortney and Eric Morgen, with both being very much involved as the CEO and COO respectively.
BioAge Labs has raised more than $300M in total from a large variety of investors. Most notably both Lilly and Amgen are on this list of investors, although we do not know the size of their investments. The most recent funding was a $170M series D round in February of 2024, which was lead by Sofinnova.
The company recently announced the closing of their IPO on the Nasdaq stock exchange, and as of September 26, 2024 they are trading as BIOA.
Although, they had a bit of a rocky start in the market hopefully investors will take to the company. According to the announcement made by BioAge this milestone will enable their development of novel therapies that treat metabolic diseases by harnessing the biology of aging.
In terms of partnerships the company entered a collaboration with Novartis in December of 2024 aiming to expand their capacity to identify & advance novel drug targets. BioAge Labs will receive an initial $20M in funding for research, and the partnership allows for another $530M in future long-term research, development, and commercial milestones.
As such BioAge Labs appears well-funded and hopefully we can expect the continued development on all of their pipeline programs.
If you want to learn more about BioAge Labs you can view their official website through this link.
Read about more anti-aging companies on this website through this link.
